Related Experiment Video
Updated: Jun 24, 2025
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Covalent Organic Frameworks as Potential Drug Carriers and Chemotherapeutic Agents for Ovarian Cancers
Atikur Hassan1,2, Sraddhya Roy3, Ananya Das3
1Department of Chemistry, Indian Institute of Technology Patna, Patna 801106, Bihar, India.
Abstract:
Anticancer drugs are often associated with limitations such as poor stability in aqueous solutions, limited cell membrane permeability, nonspecific targeting, and irregular drug release when taken orally. One possible solution to these problems is the use of nanocarriers of drug molecules, particularly those with targeting ability, stimuli-responsive properties, and high drug loading capacity. These nanocarriers can improve drug stability, increase cellular uptake, allow specific targeting of cancer cells, and provide controlled drug release. While improving the therapeutic efficacy of cancer drugs, contemporary researchers also aim to reduce their associated side effects, such that cancer patients are offered with a more effective and targeted treatment strategy. Herein, a set of nine porous covalent organic frameworks (COFs) were tested as drug delivery nanocarriers. Among these, paclitaxel loaded in COF-3 was most effective against the proliferation of ovarian cancer cells. This study highlights the emerging potential of COFs in the field of therapeutic drug delivery. Due to their biocompatibility, these porous COFs provide a viable substrate for controlled drug release, making them attractive candidates for improving drug delivery systems. This work also demonstrates the potential of COFs as efficient drug delivery agents, thereby opening up new opportunities in the field of sarcoma therapy.
Insights
Porous covalent organic frameworks (COFs) show promise as nanocarriers for anticancer drugs, improving stability and targeting. Paclitaxel loaded in COF-3 effectively inhibited ovarian cancer cell proliferation, highlighting COFs
Area of Science:
- Materials Science
- Nanotechnology
- Oncology
Background:
- Conventional anticancer drugs face challenges including poor solubility, limited cell permeability, and nonspecific targeting.
- Nanocarrier systems offer potential solutions by enhancing drug stability, cellular uptake, and targeted delivery.
- Reducing side effects while improving therapeutic efficacy is a key goal in cancer treatment strategies.
Purpose of the Study:
- To evaluate porous covalent organic frameworks (COFs) as novel nanocarriers for drug delivery.
- To assess the efficacy of paclitaxel-loaded COFs against ovarian cancer cells.
- To explore the potential of COFs in improving targeted cancer therapy and reducing drug side effects.
Main Methods:
- Synthesis and characterization of nine different porous covalent organic frameworks (COFs).
- Loading of paclitaxel, an anticancer drug, into the selected COFs.
- In vitro testing of paclitaxel-loaded COF-3 against ovarian cancer cell proliferation.
Main Results:
- Paclitaxel loaded into COF-3 demonstrated significant efficacy in inhibiting ovarian cancer cell proliferation.
- The porous COFs exhibited biocompatibility and potential for controlled drug release.
- COF-3 emerged as a particularly effective nanocarrier for paclitaxel delivery.
Conclusions:
- Porous covalent organic frameworks (COFs) represent a promising platform for developing advanced drug delivery systems.
- COFs can enhance the stability, targeting, and controlled release of anticancer drugs.
- This study underscores the potential of COFs for improved cancer therapeutics, including sarcoma treatment.
More Related Videos
08:42Microfluidic-based Synthesis of Covalent Organic Frameworks COFs: A Tool for Continuous Production of COF Fibers and Direct Printing on a Surface
Published on: July 10, 2017
04:07Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Related Concept Videos
01:25Drug-Receptor Bonds
In...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...